Skip to main content

IDEAYA Biosciences, Inc. (IDYA)

NASDAQ: IDYA · IEX Real-Time Price · USD
23.54 1.00 (4.44%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap906.23M
Revenue (ttm)35.55M
Net Income (ttm)-36.69M
Shares Out38.50M
EPS (ttm)-1.12
PE Ration/a
Forward PE4.65
Dividendn/a
Ex-Dividend Daten/a
Volume375,360
Open23.00
Previous Close22.54
Day's Range22.38 - 23.71
52-Week Range12.40 - 28.00
Beta1.55
AnalystsStrong Buy
Price Target31.00 (+31.7%)
Earnings DateNov 11, 2021

About IDYA

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients wit...

IndustryBiotechnology
IPO DateMay 23, 2019
CEOYujiro Hata
Employees83
Stock ExchangeNASDAQ
Ticker SymbolIDYA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is 31.00, which is an increase of 31.69% from the latest price.

Price Target
$31.00
(31.69% upside)
Analyst Consensus: Strong Buy

News

IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination ...

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and develop...

1 day ago - PRNewsWire

IDEAYA Biosciences to Participate in Investor Conferences in December 2021

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...

1 week ago - PRNewsWire

IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizo...

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...

1 week ago - PRNewsWire

IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...

3 weeks ago - PRNewsWire

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

IDEAYA Biosciences, Inc. (IDYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

IDEAYA Biosciences to Participate in Investor Conferences in November 2021

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and develo...

1 month ago - PRNewsWire

IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer

SOUTH SAN FRANCISCO , Oct. 18, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development ...

1 month ago - PRNewsWire

IDEAYA Biosciences to Participate in Investor Conferences in September 2021

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and devel...

3 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -371.43% and -12.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Recap: IDEAYA Biosciences Q2 Earnings

Shares of IDEAYA Biosciences (NASDAQ:IDYA) decreased 0.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 44.07% year over year to ($0.33), wh...

3 months ago - Benzinga

IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...

3 months ago - PRNewsWire

IDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August...

SOUTH SAN FRANCISCO, Calif., Aug. 2, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

4 months ago - PRNewsWire

IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Add...

SOUTH SAN FRANCISCO, Calif., July 12, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common stock ...

4 months ago - PRNewsWire

IDEAYA Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at...

5 months ago - PRNewsWire

Ideaya Biosciences Launches Equity Offering Of $80M

Ideaya Biosciences Inc (NASDAQ: IDYA) has offered up to $80 million shares in an underwritten public offering.  Underwriters have an option to purchase up to $12 million of shares.

5 months ago - Benzinga

IDEAYA Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $80 million of shares of its common stock in an u...

5 months ago - PRNewsWire

IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib C...

SOUTH SAN FRANCISCO, Calif., June 28, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and develo...

5 months ago - PRNewsWire

IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

6 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -27.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and develop...

6 months ago - PRNewsWire

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical...

SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

6 months ago - PRNewsWire

IDEAYA to Participate in Upcoming May 2021 Investor Relations Event

SOUTH SAN FRANCISCO, Calif., May 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develop...

7 months ago - PRNewsWire

IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021

SOUTH SAN FRANCISCO, Calif., April 19, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

7 months ago - PRNewsWire

IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binime...

SOUTH SAN FRANCISCO, Calif., April 16, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

7 months ago - PRNewsWire

IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monothera...

SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

7 months ago - PRNewsWire